

Benjamin G Neel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6983869/publications.pdf>

Version: 2024-02-01

151
papers

22,085
citations

8181

76
h-index

8866

145
g-index

158
all docs

158
docs citations

158
times ranked

21784
citing authors

#	ARTICLE	IF	CITATIONS
1	The "Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences, 2003, 28, 284-293.	7.5	1,093
2	Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 1995, 80, 729-738.	28.9	952
3	STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature, 2003, 421, 856-859.	27.8	914
4	Protein tyrosine phosphatases in signal transduction. Current Opinion in Cell Biology, 1997, 9, 193-204.	5.4	749
5	Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nature Genetics, 2007, 39, 70-74.	21.4	534
6	From Form to Function: Signaling by Protein Tyrosine Phosphatases. Cell, 1996, 87, 365-368.	28.9	529
7	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell, 2017, 170, 1079-1095.e20.	28.9	522
8	Activating Mutations of the Noonan Syndrome-Associated <i>SHP2/PTPN11</i> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
9	Combinatorial control of the specificity of protein tyrosine phosphatases. Current Opinion in Cell Biology, 2001, 13, 182-195.	5.4	470
10	Mathematical Models of Protein Kinase Signal Transduction. Molecular Cell, 2002, 9, 957-970.	9.7	461
11	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell, 2016, 164, 293-309.	28.9	399
12	Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment. Molecular Cell, 2004, 13, 341-355.	9.7	395
13	Mouse model of Noonan syndrome reveals cell type- and gene dosage- dependent effects of Ptpn11 mutation. Nature Medicine, 2004, 10, 849-857.	30.7	384
14	The "Gab"™ in signal transduction. Trends in Cell Biology, 2003, 13, 122-130.	7.9	354
15	The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer and Metastasis Reviews, 2008, 27, 179-192.	5.9	343
16	Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 2002, 1, 479-492.	16.8	327
17	The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early xenopus development. Cell, 1995, 80, 473-483.	28.9	326
18	Leptin and Insulin Act on POMC Neurons to Promote the Browning of White Fat. Cell, 2015, 160, 88-104.	28.9	308

#	ARTICLE	IF	CITATIONS
19	Divergent Roles of SHP-2 in ERK Activation by Leptin Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 4747-4755.	3.4	304
20	Cloning of p97/Gab2, the Major SHP2-Binding Protein in Hematopoietic Cells, Reveals a Novel Pathway for Cytokine-Induced Gene Activation. <i>Molecular Cell</i> , 1998, 2, 729-740.	9.7	296
21	Essential role for Gab2 in the allergic response. <i>Nature</i> , 2001, 412, 186-190.	27.8	289
22	Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. <i>Structure</i> , 1998, 6, 249-254.	3.3	283
23	Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells. <i>Cancer Discovery</i> , 2012, 2, 172-189.	9.4	276
24	PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects. <i>Journal of Biological Chemistry</i> , 2006, 281, 6785-6792.	3.4	272
25	Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. <i>Nature Genetics</i> , 2000, 24, 296-299.	21.4	268
26	Diverse Biochemical Properties of Shp2 Mutants. <i>Journal of Biological Chemistry</i> , 2005, 280, 30984-30993.	3.4	256
27	Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. <i>Cancer Cell</i> , 2005, 7, 179-191.	16.8	252
28	The role of Shp2 (PTPN11) in cancer. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 23-30.	3.3	246
29	New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Molecular and Cellular Biology</i> , 2000, 20, 7109-7120.	2.3	241
30	Receptor-Specific Regulation of Phosphatidylinositol 3-Kinase Activation by the Protein Tyrosine Phosphatase Shp2. <i>Molecular and Cellular Biology</i> , 2002, 22, 4062-4072.	2.3	234
31	B Cell-Specific Deletion of Protein-Tyrosine Phosphatase Shp1 Promotes B-1a Cell Development and Causes Systemic Autoimmunity. <i>Immunity</i> , 2007, 27, 35-48.	14.3	231
32	Regulation of Receptor Tyrosine Kinase Signaling by Protein Tyrosine Phosphatase-1B. <i>Journal of Biological Chemistry</i> , 2003, 278, 739-744.	3.4	226
33	An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival. <i>Developmental Cell</i> , 2006, 10, 317-327.	7.0	222
34	Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. <i>Journal of Clinical Investigation</i> , 2011, 121, 1026-1043.	8.2	219
35	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. <i>Cancer Discovery</i> , 2018, 8, 1237-1249.	9.4	216
36	Regulation of Early Events in Integrin Signaling by Protein Tyrosine Phosphatase SHP-2. <i>Molecular and Cellular Biology</i> , 1999, 19, 3205-3215.	2.3	204

#	ARTICLE	IF	CITATIONS
37	Intramolecular Regulation of Protein Tyrosine Phosphatase SH-PTP1: A New Function for Src Homology 2 Domains. <i>Biochemistry</i> , 1994, 33, 15483-15493.	2.5	202
38	SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130. <i>Journal of Biological Chemistry</i> , 2003, 278, 661-671.	3.4	201
39	A role for the scaffolding adapter GAB2 in breast cancer. <i>Nature Medicine</i> , 2006, 12, 114-121.	30.7	198
40	Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6625-6630.	7.1	191
41	Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. <i>Nature</i> , 2013, 499, 491-495.	27.8	190
42	Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages. <i>Molecular and Cellular Biology</i> , 1998, 18, 3838-3850.	2.3	189
43	Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6468-6473.	7.1	188
44	Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors. <i>Journal of Biological Chemistry</i> , 2003, 278, 41677-41684.	3.4	186
45	MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation. <i>Journal of Clinical Investigation</i> , 2011, 121, 1009-1025.	8.2	184
46	Stops along the RAS pathway in human genetic disease. <i>Nature Medicine</i> , 2006, 12, 283-285.	30.7	181
47	Nonreceptor Protein-Tyrosine Phosphatases in Immune Cell Signaling. <i>Annual Review of Immunology</i> , 2007, 25, 473-523.	21.8	174
48	Next-generation sequencing identifies rare variants associated with Noonan syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11473-11478.	7.1	158
49	Role of phosphatases in lymphocyte activation. <i>Current Opinion in Immunology</i> , 1997, 9, 405-420.	5.5	157
50	Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and "Redoxome" Cell, 2011, 146, 826-840.	28.9	156
51	Vitamin C in Stem Cell Reprogramming and Cancer. <i>Trends in Cell Biology</i> , 2018, 28, 698-708.	7.9	139
52	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	138
53	Genetic analysis of protein tyrosine phosphatases. <i>Current Opinion in Genetics and Development</i> , 1998, 8, 112-126.	3.3	132
54	Control of CNS Cell-Fate Decisions by SHP-2 and Its Dysregulation in Noonan Syndrome. <i>Neuron</i> , 2007, 54, 245-262.	8.1	128

#	ARTICLE	IF	CITATIONS
55	The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. <i>Current Biology</i> , 1998, 8, 1009-1017.	3.9	125
56	Structural Determinants of SHP-2 Function and Specificity in <i>Xenopus</i> Mesoderm Induction. <i>Molecular and Cellular Biology</i> , 1998, 18, 161-177.	2.3	125
57	SHP1 Phosphatase-Dependent T Cell Inhibition by CEACAM1 Adhesion Molecule Isoforms. <i>Immunity</i> , 2006, 25, 769-781.	14.3	123
58	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. <i>Molecular Cell</i> , 2017, 65, 347-360.	9.7	123
59	Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. <i>Nature Neuroscience</i> , 2014, 17, 1736-1743.	14.8	120
60	Structure and function of SH2-domain containing tyrosine phosphatases. <i>Seminars in Cell Biology</i> , 1993, 4, 419-432.	3.4	112
61	Activated Mutants of SHP-2 Preferentially Induce Elongation of <i>Xenopus</i> Animal Caps. <i>Molecular and Cellular Biology</i> , 2000, 20, 299-311.	2.3	112
62	Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. <i>Blood</i> , 2009, 113, 4414-4424.	1.4	107
63	SHPS-1 is a scaffold for assembling distinct adhesion-regulated multi-protein complexes in macrophages. <i>Current Biology</i> , 1999, 9, 927-S4.	3.9	103
64	Noonan syndrome cardiac defects are caused by <i>PTPN11</i> acting in endocardium to enhance endocardial-mesenchymal transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4736-4741.	7.1	103
65	SHP2 Tyrosine Phosphatase Converts Parafibromin/Cdc73 from a Tumor Suppressor to an Oncogenic Driver. <i>Molecular Cell</i> , 2011, 43, 45-56.	9.7	97
66	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. <i>Developmental Cell</i> , 2010, 18, 750-762.	7.0	96
67	PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. <i>Nature Cell Biology</i> , 2016, 18, 803-813.	10.3	95
68	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i> -Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480.	1.6	94
69	CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity. <i>Nature Immunology</i> , 2004, 5, 651-657.	14.5	90
70	The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. <i>Oncogene</i> , 2002, 21, 5175-5181.	5.9	88
71	Site-Selective Regulation of Platelet-Derived Growth Factor β Receptor Tyrosine Phosphorylation by T-Cell Protein Tyrosine Phosphatase. <i>Molecular and Cellular Biology</i> , 2004, 24, 2190-2201.	2.3	87
72	Substrate Specificity of Protein Tyrosine Phosphatases 1B, RPTP β , SHP-1, and SHP-2. <i>Biochemistry</i> , 2011, 50, 2339-2356.	2.5	87

#	ARTICLE	IF	CITATIONS
73	Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2. <i>Cell Metabolism</i> , 2014, 20, 85-102.	16.2	83
74	SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase. <i>Journal of Cell Biology</i> , 2003, 163, 999-1010.	5.2	82
75	Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. <i>Blood</i> , 2011, 117, 4253-4261.	1.4	82
76	Deletion of <i>Ptpn11</i> (Shp2) in Cardiomyocytes Causes Dilated Cardiomyopathy via Effects on the Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase and RhoA Signaling Pathways. <i>Circulation</i> , 2008, 117, 1423-1435.	1.6	79
77	Scaffolding Adapter Grb2-Associated Binder 2 Requires Syk to Transmit Signals from Fc μ RI. <i>Journal of Immunology</i> , 2006, 176, 2421-2429.	0.8	78
78	Characterization of Two SHP-2-associated Binding Proteins and Potential Substrates in Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 16421-16430.	3.4	76
79	The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1. <i>Cancer Cell</i> , 2014, 25, 181-195.	16.8	76
80	The Scaffolding Adapter Gab2, via Shp-2, Regulates Kit-evoked Mast Cell Proliferation by Activating the Rac/JNK Pathway. <i>Journal of Biological Chemistry</i> , 2006, 281, 28615-28626.	3.4	75
81	The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common β Chain-using Cytokines. <i>Journal of Biological Chemistry</i> , 2000, 275, 26959-26966.	3.4	75
82	Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. <i>Blood</i> , 2013, 121, 4205-4220.	1.4	74
83	The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. <i>International Immunology</i> , 1999, 11, 1999-2014.	4.0	73
84	Sticking It to Cancer with Molecular Glue for SHP2. <i>Cancer Cell</i> , 2016, 30, 194-196.	16.8	72
85	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E468-E477.	7.1	72
86	Cutting Edge: Gab2 Mediates an Inhibitory Phosphatidylinositol 3 α -Kinase Pathway in T Cell Antigen Receptor Signaling. <i>Journal of Immunology</i> , 2000, 165, 4158-4163.	0.8	68
87	Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. <i>Human Mutation</i> , 2015, 36, 1080-1087.	2.5	67
88	Protein-tyrosine Phosphatase SHP-1 Is Dispensable for Fc γ RIIB-mediated Inhibition of B Cell Antigen Receptor Activation. <i>Journal of Biological Chemistry</i> , 1997, 272, 20038-20043.	3.4	66
89	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 384-407.	9.4	64
90	Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. <i>Seminars in Immunology</i> , 1998, 10, 329-347.	5.6	62

#	ARTICLE	IF	CITATIONS
91	A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. <i>Blood</i> , 2010, 116, 3611-3621.	1.4	60
92	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	9.4	58
93	Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor-Activating Mutations. <i>Cancer Research</i> , 2010, 70, 3843-3850.	0.9	55
94	Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). <i>BMC Structural Biology</i> , 2014, 14, 10.	2.3	55
95	Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	51
96	Inhibition of IFN- γ signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10267-10272.	7.1	50
97	SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. <i>Journal of Cell Biology</i> , 2006, 175, 87-97.	5.2	50
98	The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis. <i>Cell Reports</i> , 2020, 30, 215-228.e5.	6.4	50
99	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. <i>Cancer Discovery</i> , 2021, 11, 362-383.	9.4	50
100	Phosphorylation of Protein-tyrosine Phosphatase PTP-1B on Identical Sites Suggests Activation of a Common Signaling Pathway during Mitosis and Stress Response in Mammalian Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 2957-2962.	3.4	46
101	Altered Glucose Homeostasis in Mice with Liver-specific Deletion of Src Homology Phosphatase 2. <i>Journal of Biological Chemistry</i> , 2010, 285, 39750-39758.	3.4	46
102	Off-target inhibition by active site-targeting SHP2 inhibitors. <i>FEBS Open Bio</i> , 2018, 8, 1405-1411.	2.3	44
103	Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2. <i>Nature Communications</i> , 2017, 8, 466.	12.8	43
104	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 1022-1045.	9.4	43
105	Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2. <i>Molecular Pharmacology</i> , 2005, 68, 41-48.	2.3	42
106	Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 984-989.	7.1	41
107	Genetic and cellular mechanisms of oncogenesis. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 1-2.	3.3	40
108	SOS1 mutations are rare in human malignancies: Implications for Noonan syndrome patients. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 253-259.	2.8	40

#	ARTICLE	IF	CITATIONS
109	Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia. <i>Cancer Research</i> , 2018, 78, 75-87.	0.9	39
110	Methods to monitor classical proteinâ€”tyrosine phosphatase oxidation. <i>FEBS Journal</i> , 2013, 280, 459-475.	4.7	38
111	Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2. <i>Nature Communications</i> , 2013, 4, 2037.	12.8	38
112	Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2017, 18, 2343-2358.	6.4	38
113	Receptor-Type Protein-Tyrosine Phosphatase $\frac{1}{4}$ Is Expressed in Specific Vascular Endothelial Beds in Vivo. <i>Experimental Cell Research</i> , 1999, 248, 329-338.	2.6	36
114	Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated <i>RAF1</i> Mutants. <i>Molecular and Cellular Biology</i> , 2012, 32, 3872-3890.	2.3	35
115	Hepatocyte-Specific <i>Ptpn6</i> Deletion Protects From Obesity-Linked Hepatic Insulin Resistance. <i>Diabetes</i> , 2012, 61, 1949-1958.	0.6	34
116	Tyrosine phosphatase SHP-2 is a mediator of activity-dependent neuronal excitotoxicity. <i>EMBO Journal</i> , 2005, 24, 305-314.	7.8	33
117	The Signaling Adaptor Gab1 Regulates Cell Polarity by Acting as a PAR Protein Scaffold. <i>Molecular Cell</i> , 2012, 47, 469-483.	9.7	33
118	SHP2 regulates skeletal cell fate by modifying SOX9 expression and transcriptional activity. <i>Bone Research</i> , 2018, 6, 12.	11.4	33
119	A ERK/RSKâ€”mediated negative feedback loop regulates Mâ€”CSFâ€”evoked PI3K/AKT activation in macrophages. <i>FASEB Journal</i> , 2018, 32, 875-887.	0.5	31
120	N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. <i>Cell Systems</i> , 2019, 8, 345-351.e4.	6.2	31
121	Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. <i>Cell Reports</i> , 2017, 18, 2932-2942.	6.4	28
122	Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. <i>Science Signaling</i> , 2018, 11, .	3.6	27
123	SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	26
124	Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. <i>Journal of Experimental Medicine</i> , 2016, 213, 25-34.	8.5	25
125	Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase δ . <i>Molecular Cell</i> , 2020, 80, 682-698.e7.	9.7	25
126	Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. <i>Blood</i> , 2016, 127, 1803-1813.	1.4	24

#	ARTICLE	IF	CITATIONS
127	Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome. <i>Nature Communications</i> , 2017, 8, 15518.	12.8	23
128	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. <i>American Journal of Pathology</i> , 2018, 188, 1120-1131.	3.8	23
129	Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer Therapy. <i>Cell</i> , 2020, 181, 514-517.	28.9	23
130	The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. <i>PLoS Genetics</i> , 2019, 15, e1008108.	3.5	22
131	An eye on organ development. <i>Nature</i> , 2003, 426, 238-239.	27.8	18
132	Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. <i>Journal of Biological Chemistry</i> , 2020, 295, 18036-18050.	3.4	16
133	SH2 Domain-Containing Protein-Tyrosine Phosphatases. , 2010, , 771-809.		14
134	Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1). <i>Journal of Biological Chemistry</i> , 2016, 291, 15641-15652.	3.4	14
135	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 6539-6548.	0.9	12
136	Role of PTPN11 (SHP2) in Cancer. , 2016, , 115-143.		11
137	Identification of a Domain in the β^2 Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs. <i>Journal of Biological Chemistry</i> , 1998, 273, 5577-5581.	3.4	10
138	From an orphan disease to a generalized molecular mechanism. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e26657.	1.8	10
139	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	10
140	Leukemogenic Ptpn11 Allele Causes Defective Erythropoiesis in Mice. <i>PLoS ONE</i> , 2014, 9, e109682.	2.5	8
141	SH2-Domain-Containing Protein-Tyrosine Phosphatases. , 2003, , 707-728.		7
142	MMD-associated <i>RNF213</i> SNPs encode dominant-negative alleles that globally impair ubiquitylation. <i>Life Science Alliance</i> , 2022, 5, e202000807.	2.8	7
143	Tyrosyl phosphorylation toggles a Runx1 switch. <i>Genes and Development</i> , 2012, 26, 1520-1526.	5.9	4
144	Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13823-13832.	3.5	4

#	ARTICLE	IF	CITATIONS
145	Activated Thiol Sepharoseâ€based proteomic approach to quantify reversible protein oxidation. FASEB Journal, 2019, 33, 12336-12347.	0.5	3
146	U.S. Biomedical Research Needs More Immigrant Scientists, Not Fewer!. Cancer Cell, 2020, 38, 308.	16.8	2
147	Hidesaburo Hanafusa 1929â€2009. Cell, 2009, 137, 197-199.	28.9	1
148	Hidesaburo Hanafusa 1929â€2009. Molecular Cell, 2009, 34, 141-143.	9.7	0
149	New pROSpects for PTP1B: micro-Managing Oncogene-Induced Senescence. Molecular Cell, 2014, 55, 651-653.	9.7	0
150	Redox Regulation of PTPs in Metabolism: Focus on Assays. , 2013, , 1-26.		0
151	Raymond L. Erikson (1936â€2020). Cell, 2020, 181, 961-963.	28.9	0